Drug Trial Radar · NCT07057414
The Safety and Efficacy of GMDTC for Injection in Subjects With Elevated Cadmium Levels
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
22
Actual
Start
Jul 7, 2025
Primary completion
Jan 26, 2026
Study completion Mar 4, 2026
Sponsor
- Lead sponsor
- Guangdong Jianersheng Pharmaceutical Technology Co., Ltd.Academic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Guangdong Provincial Hospital for Occupational Disease Prevention and Treatment
- First posted
- Jul 9, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled, single-center Phase IIa clinical study.
Conditions
- Cadmium Exceeds the Standard
Interventions
GMDTC for injectionDrug
GMDTC for Injection with a specification of 0.5g/vial, and administered by intravenous infusion. According to the drug preparation SOP , Using 0.9% physiological saline to achieve the required concentration for each dose group (Dose Group 1: 2 g reconstituted in 500 mL, final concentration 4 mg/mL; Dose Group 2: 1.5 g reconstituted in 500 mL , final concentration 3 mg/mL). All infusion-related reactions must be documented. Drug preparation must be performed by an non-blind investigator independent of the study to maintain blinding integrity for other study personnel.
0.9% Sodium Chloride Injection(0.9% NaCl)Other
0.9% Sodium Chloride Injection with a specification of 500mL/bag, and administered by intravenous infusion. The infusion volume should be equal in volume to the corresponding investigational drug at the same dose in the experimental group. All infusion-related reactions must be documented. Drug preparation must be performed by a non-blind investigator independent of the study to maintain blinding integrity for other study personnel.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacodynamic Parameters , 24-hour urinary cadmiumTime frame: Evaluated at pre-dose (Day-1) and post-dose (Day1-Day6, Day8-Day13)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Guangdong Provincial Hospital for Occupational Disease Prevention and Treatment
Guangzhou, Guangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.